Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 9/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
| ▸ | GPR3 | P46089 | 1/20 | 0.37 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21835693 | 0.85 | FFAR4 (0.41) | FFAR4HCRTR2FFAR1GPR3CYP2C9 | |
| SCHEMBL22817198 | 0.79 | SLC6A4 (0.41) | FFAR4HCRTR2FFAR1CYP2C9SCN5A | |
| SCHEMBL22817075 | 0.79 | SLC6A4 (0.41) | FFAR4HCRTR2FFAR1CYP2C9SCN5A | |
| SCHEMBL22817197 | 0.78 | HCRTR2 (0.38) | FFAR4HCRTR2FFAR1CYP2C9SCN5A | |
| SCHEMBL22817200 | 0.76 | FFAR4 (0.39) | FFAR4FFAR1BCL2L1MCL1DRD3 | |
| SCHEMBL28573225 | 0.73 | L3MBTL1 (0.43) | KCNH2 | |
| SCHEMBL20204035 | 0.73 | CXCR2 (0.37) | HCRTR2GPR3BCL2L1MCL1KIF11 | |
| SCHEMBL29894167 | 0.72 | GPR3 (0.48) | FFAR4FFAR1GPR3CYP2C9SCN5A | |
| SCHEMBL8065084 | 0.72 | GPR3 (0.48) | FFAR4FFAR1GPR3CYP2C9SCN5A | |
| SCHEMBL11065683 | 0.69 | FFAR4 (0.48) | FFAR4FFAR1GPR3CYP2C9SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20210188852-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2018098499-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188852-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | FFAR4 3542/4885HCRTR2 320/4885FFAR1 3323/4885 |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | FFAR4 3542/4885HCRTR2 320/4885FFAR1 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.